Levofloxacin mesylate

Levofloxacin mesylate.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2?), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. This product has little effect on the metabolism of theophylline, but the blood drug concentration of theophylline should still be measured and the dosage adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood drug concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should also be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increased blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (t1/2beta;), and may cause central nervous system toxicity. 7. Acid-reducing drugs and iron preparations containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together. 8. When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions occasionally occur, so it is not suitable for use with fenbufen.

The main ingredients of this product are: Levofloxacin mesylate

1. This product cannot be used in the same infusion tube with polyvalent metal ion solutions such as magnesium and calcium. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. 2. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. 3. When used simultaneously with non-steroidal anti-inflammatory drugs, convulsions may be induced. 4. When used simultaneously with oral hypoglycemic drugs, hypoglycemia may be caused. Therefore, attention should be paid to monitoring blood sugar concentration during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

The main ingredients of this product are: Levofloxacin mesylate

1. This product cannot be used in the same infusion tube with polyvalent metal ion solutions such as magnesium and calcium. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. 2. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. 3. When used simultaneously with non-steroidal anti-inflammatory drugs, convulsions may be induced. 4. When used simultaneously with oral hypoglycemic drugs, hypoglycemia may be caused. Therefore, attention should be paid to monitoring blood sugar concentration during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.